Aytu BioPharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 150
- Market Cap
- -
- Website
- http://www.aytubio.com
Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
Phase 3
Suspended
- Conditions
- Vascular Ehlers-Danlos Syndrome
- Interventions
- Drug: EnzastaurinDrug: Placebo
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Aytu BioPharma, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05463679
- Locations
- 🇺🇸
Aytu BioPharma, Englewood, Colorado, United States
Respiratory COVID-19: A Randomized, Sham-Controlled Study
Not Applicable
Withdrawn
- Conditions
- COVID-19 PneumoniaCOVID-19 Respiratory InfectionAcute Respiratory Distress SyndromeCOVID-19 Acute Respiratory Distress Syndrome
- Interventions
- Device: UVA Light Emitting CatheterDevice: Sham Control Catheter
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Aytu BioPharma, Inc.
- Registration Number
- NCT05166915
- Locations
- 🇪🇸
Hospital Clinic of Barcelona, Barcelona, Catalan, Spain
🇪🇸Vall d'Hebron University Hospital, Barcelona, Catalan, Spain
A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0
Withdrawn
- Conditions
- Male Infertility
- Interventions
- Diagnostic Test: Diagnostic
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Aytu BioPharma, Inc.
- Registration Number
- NCT02839447
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Miami, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath